Curevo Vaccine

Curevo Vaccine is a private, clinical-stage biotech founded in 2020 and based in Seattle, USA, developing adjuvanted subunit vaccines as an alternative to mRNA and live-attenuated platforms. The company's lead program, amezosvatein, has generated Phase 2 data showing non-inferior immunogenicity to the market leader Shingrix® for shingles, alongside a significantly improved tolerability profile. Curevo's strategy is to address vaccine hesitancy and accessibility issues, with plans to expand development into immunocompromised populations for chickenpox. The company is currently pre-revenue, advancing its lead candidate toward Phase 3 trials.

Adjuvanted subunit vaccine platform focused on developing non-mRNA vaccines with improved tolerability and suitability for immunocompromised populations.

In shingles, Curevo's direct and formidable competitor is GSK's Shingrix®, the dominant global product. Competitive differentiation is based entirely on demonstrating a superior tolerability profile. In the potential chickenpox indication for the immunocompromised, Curevo would face little direct competition, as current live-attenuated vaccines are contraindicated, making it a potential first-in-class option.